



Reate Pharmaceuticals (USA): Constituent Deletion

Changes in FTSE RAFI™ Index Series

21 September 2023

Subject to the completion of the cash acquisition of Reate Pharmaceuticals (USA, constituent), by Biogen Inc., please see details of affected indexes and effective dates below:

Index	Effective From Start of Trading
FTSE RAFI US 1500 Mid Small Index - QSR	26 September 2023

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia	+1800 653 680
Hong Kong	+852 2164 3333
Japan	+81 3 6441 1430
London	+44 (0) 20 7866 1810
New York	+1866 551 0617

Alternatively please visit our website at www.ftserussell.com

[Terms of Use](#) | Copyright © 2023 FTSE Russell